Full Text View
Tabular View
No Study Results Posted
Related Studies
Methylene Blue for Cognitive Dysfunction in Bipolar Disorder
This study has been completed.
Study NCT00214877   Information provided by Capital District Health Authority, Canada
First Received: September 20, 2005   Last Updated: March 28, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bipolar Disorder
Additional conditions recognized in this trial
Cognition Disorders
Disease
More general conditions related to this trial
Affective Disorders, Psychotic
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Mood Disorders
Pathologic Processes
Interventions listed in this trial
Methylene Blue
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sponsors listed in this trial
Capital District Health Authority, Canada
Stanley Medical Research Institute


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services